NanoViricides is trading $1.31 (+5.65%) after announcing preparations for a Phase II clinical-trial protocol for NV-387 as a measles treatment.
- On August 31, 2026, the company cited rising measles cases and FDA-granted Orphan Drug and Rare Pediatric Disease designations, potentially supporting future development incentives.
- The trial has not begun, and no IND has been filed or cleared; volume data was unavailable.